Pyrazole Derivatives Inhibit c-MYC DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule inhibitors face challenges in effectively targeting the c-MYC oncogene due to its 'undruggable' nature, particularly in disrupting Myc-Max interactions without causing DNA damage, which limits their therapeutic potential in cancer treatment.
Innovation Solution
Development of substituted heterocycles, specifically pyrazole derivatives, that selectively inhibit c-MYC-driven cell proliferation by interfering with the Myc/Max complex's DNA binding, thereby inhibiting cancer cell growth without causing significant DNA damage at low concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target c-MYC, then the ability to inhibit c-MYC-driven cell proliferation is improved, but the risk of causing DNA damage increases
Solution Approach 1:
The patent segments the c-MYC targeting mechanism into two distinct functional components: (1) inhibition of c-MYC DNA binding activity through direct interaction with the c-MYC protein, and (2) selective disruption of c-MYC/Max heterodimer formation. This segmentation allows the compound to achieve anti-proliferative effects through multiple pathways while avoiding DNA damage, as evidenced by the compound's ability to inhibit c-MYC-driven cell lines without causing genotoxicity in vitro
Solution Approach 2:
The compound acts as an intermediary that binds to the c-MYC protein and prevents its interaction with DNA and Max protein. By positioning itself as a molecular mediator between c-MYC and its targets, the compound blocks c-MYC's oncogenic functions without requiring direct DNA interaction, thereby achieving selective inhibition without DNA damage
2Adaptability or versatility
If small molecule inhibitors are designed to disrupt Myc-Max interactions, then the specificity for c-MYC targeting is improved, but the difficulty in achieving effective inhibition increases
Solution Approach 1:
The patent employs parameter changes in the molecular structure of the compound to optimize its binding affinity and specificity for c-MYC. By systematically varying structural parameters (such as substituent groups on the core scaffold) and evaluating their impact on c-MYC binding and cellular activity, the researchers identified compounds with optimal balance between specificity and potency, overcoming the inherent difficulty in targeting transcription factors
3Ease of operation
If conventional small molecule approaches are used to target transcription factors, then the ease of administration is maintained, but the effectiveness of inhibition is reduced
Solution Approach 1:
The patent introduces dynamic adaptability into the small molecule inhibitor by designing a compound that can adapt its binding mode to interact with multiple regions of the c-MYC protein. This dynamic binding capability allows the compound to effectively inhibit c-MYC function despite the flexibility and conformational changes of the transcription factor, thereby achieving reliable inhibition while maintaining the ease of administration associated with small molecules
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are substituted heterocycles compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.